Breaking News

BioFactura Establishes CDMO Division

Capitol Biologics will provide process development, early-phase clinical manufacturing, and analytical services to emerging biotechnology companies and U.S. government agencies.

Author Image

By: Charlie Sternberg

Associate Editor

BioFactura, Inc., a clinical-stage biopharmaceutical company focused on biosimilars and biodefense medical countermeasures, has established Capitol Biologics, a new Contract Development and Manufacturing Organization (CDMO) division. This division provides process development, early-phase clinical manufacturing, and analytical services to emerging biotechnology companies and U.S. government agencies. Located in the BioHealth Capital Region, Capitol Biologics leverages BioFactura’s technical a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters